Core Insights - DBV Technologies held its Combined General Meeting where shareholders approved all proposed resolutions [1][2] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3] - The company is investigating its proprietary technology platform, Viaskin™, which aims to address food allergies through epicutaneous immunotherapy (EPIT™) [3] - Viaskin is designed to introduce microgram amounts of biologically active compounds to the immune system via intact skin, aiming to modify the underlying allergy by re-educating the immune system [3] - The company is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for Viaskin Peanut targeting peanut allergic toddlers and children [3] Operations and Trading - DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ [4] - The company's ordinary shares are traded on segment B of Euronext Paris and its American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market [4]